Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
Mohammed Hassan‐Alin(AstraZeneca (United Kingdom)), Kerstin Röhss(AstraZeneca (Sweden)), Eva Bredberg(AstraZeneca (United Kingdom)), T. Andersonn(AstraZeneca (United States))
Cited by 140
Related Papers
Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole
|Alimentary Pharmacology & Therapeutics|2001|175
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
|British Journal of Clinical Pharmacology|1998|124
Effect of Esomeprazole 40 mg vs Omeprazole 40 mg on 24-Hour Intragastric pH in Patients with Symptoms of Gastroesophageal Reflux Disease
|Digestive Diseases and Sciences|2002|93
Effect of Once Daily Intravenous and Oral Omeprazole on 24-Hour Intragastric Acidity in Healthy Subjects
|Scandinavian Journal of Gastroenterology|1993|58